Characterization of the rat neurofibromatosis 2 gene and its involvement in asbestos-induced mesothelioma

Molecular Carcinogenesis

Volumn 18, Issue 1, 1997, Pages 54-60

  Kleymenova, Elena V ^a   Bianchi, Albert A ^b   Kley, Nikolai ^b   Pylev, Lev N ^c   Walker, Cheryl L ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

carcinogenesis; mesothelium; mineral fibers; tumor suppressor gene

Indexed keywords

ASBESTOS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; GENE MUTATION; MESOTHELIOMA; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

ANIMALS; ASBESTOS; BASE SEQUENCE; BLOTTING, NORTHERN; DNA; GENES, NEUROFIBROMATOSIS 2; HUMANS; MESOTHELIOMA; MOLECULAR SEQUENCE DATA; MUTATION; PERITONEAL NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RATS; RNA SPLICING; TUMOR CELLS, CULTURED;

ANIMALIA; RODENTIA;

EID: 0031038128     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199701)18:1<54::AID-MC7>3.0.CO;2-R     Document Type: Article

References (47)

1. Huncharek M. Asbestos and cancer: Epidemiological and public health controversies. Cancer Invest 12:214-222, 1994.
2. Peto J, Hodson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 345:535-539, 1995.
3. Wagner JC. Experimental production of mesothelial tumors of the pleura by implantation of dusts in laboratory animals. Nature 196:180-181, 1962.
4. Wagner JC, Berry G, Skidmore JW, Timbel V. The effects of the inhalation of asbestos in rats. Br J Cancer 29:173-179, 1974.
5. Davis JMG, Beckett ST, Bolton RE, et al. Mass and number of fibers in the pathogenesis of asbestos-related lung disease in rats. Br J Cancer 37:673-688, 1978.
6. Pott F, Ziem U, Reitter FJ, et al. Carcinogenicity studies on fibers, metal compounds, and some other dusts in rats. Exp Pathol 32:129-152, 1987.
7. Craighead JE. Current pathogenic concepts of diffuse malignant mesothelioma. Hum Pathol 18:544-557, 1987.
8. Friemann J, Muller KM, Pott F. Mesothelial proliferation due to asbestos and man-made fibers: Experimental studies on rat omentum. Pathol Res Pract 186:117-123, 1990.
9. Gerwin BI, Lecher JF, Reddel RR, et al. Comparison of production of transforming growth factor β and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines. Cancer Res 47:6180-6184, 1987.
10. Versnel MA, Hagemeijer A, Bounts MJ, Kwast TU, Hoogsteden HC. Expression of c-sis (PDGF β-chain) and PDGF α-chain genes in ten human malignant mesothelioma cell lines derived from primary and metastatic tumors. Oncogene 2:601-605, 1988.
11. Metcalf RA, Welsh JA, Bennet WP, et al. p53 and Ki-ras mutations in human mesothelioma cell lines. Cancer Res 52:2610-2615, 1992.
12. Cote RJ, Jhanwar SC, Novick S, Pellicer A. Genetic alterations of the p53 gene are a feature of malignant mesotheliomas. Cancer Res 51:5410-5416, 1991.
13. Park S, Schalling M, Bernard A, et al. The Wilms' tumor gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet 4:415-420, 1993.
14. Walker C, Rutten A, Yuan X, Pass H, Mew DM, Everitt J. Wilms' tumor suppressor gene expression in rat and human mesothelioma. Cancer Res 54:3101-3106, 1994.
15. Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 54:5547-5551, 1994.
16. Sekido T, Pass HI, Bader S, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 55:1227-1231, 1995.
17. Bianchi AB, Mitsunaga S, Cheng JQ, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 92:10854-10858, 1995.
18. Martuza RL, Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). New Engl J Med 318:684-688, 1988.
19. Wertelecki W, Rouleau GA, Superneau DW, Forehand LW. Neurofibromatosis 2: Clinical and DNA linkage studies of a large kindred. New Engl J Med 319:278-283, 1988.
20. Kaiser-Kupfer MI, Freidlin V, Datiles MB, et al. The association of posterior capsular lens opacities with bilateral acoustic neuromas in patients with neurofibromatosis type 2. Arch Ophthalmol 107:541-544, 1988.
21. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72:1-20, 1993.
22. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 363:515-521, 1993.
23. Pykett MJ, Murphy M, Harnish PR, George DL. The neurofibromatosis 2 (NF2) tumor suppressor gene encodes multiple alternatively spliced transcripts. Hum Mol Genet 3:559-564, 1993.
24. Arakawa H, Hayashi N, Nagase H, Ogawa M, Nakamura Y. Alternative splicing of the NF2 gene and its mutation analysis of breast and colorectal cancers. Hum Mol Genet 3:565-568, 1994.
25. Bianchi AB, Hara T, Ramesh V. Mutations in transcript isoforms of the neurofibromatosis type 2 in multiple human tumor types. Nat Genet 6:185-192, 1994.
26. Lutchman M, Rouleau GA. The neurofibromatosis type 2 product, schwannomin, suppresses growth of NIH 3T3 cells. Cancer Res 55:2270-2274, 1995.
27. Tikoo A, Varga M, Ramesh V, Gusellas J, Maruta H. An anti-ras function of neurofibromatosis type 2 gene product (NF2/merlin). J Biol Chem 269:23387-23390, 1994.
28. Flejter WL, Li FP, Antman KH, Testa JR. Recurring loss involving chromosomes 1, 3, and 22 in malignant mesotheliomas: Possible sites of tumor suppressor genes. Genes Chromosomes Cancer 1:148-154, 1989.
29. Craighead JE, Akley NJ, Gould LB, Libbus BL. Characteristics of tumor and tumor cells cultured from experimental asbestos-induced mesotheliomas in rats. Am J Pathol 129:448-462, 1987.
30. Palekar LD, Eyre JF, Coffin DL. Chromosomal changes associated with tumorigenic mineral fibers. In: Wehner AP, Felton D-L (eds), Proceedings of the International Symposium Workshop on the Biological Interaction of Inhaled Mineral Fibers and Cigarette Smoke, held at the Battelle Seattle Conference Center April 10-14, 1988, Seattle, WA, 1988, pp. 355-372.
31. Funaki K, Everitt J, Bermudez E, Walker C. Trisomy of rat chromosome 1 associated with mesothelial cell transformation. Cancer Res 51:4059-4066, 1991.
32. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonucleases. Biochemistry 18:5294-5299, 1979.
33. Hara T, Bianchi AB, Seizinger BR, Kley N. Molecular cloning and characterization of alternatively spliced transcripts of the mouse neurofibromatosis type 2 gene. Cancer Res 54:330-335, 1994.
34. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74:5463-5467, 1977.
35. Takeshima H, Izawa I, Lee P, Safdar N, Levin V, Saya H. Detection of cellular proteins that interact with the NF2 tumor suppressor gene product. Oncogene 9:2135-2144, 1994.
36. Gutmann D, Wright D, Geist R, Snider W. Expression of the neurofibromatosis 2 (NF2) gene isoforms during rat embryonic development. Hum Mol Genet 4:471-478, 1995.
37. Haase VH, Troffatter JA, Maccllin M, et al. The murine NF2 homologue encodes a highly conserved merlin protein with alternative forms. Hum Mol Genet 3:407-411, 1994.
38. Bakker MA, Riegman PHJ, Hekman ACP, et al. The product of the NF2 tumor suppressor gene localizes near the plasma membrane and is highly expressed in muscle cells. Oncogene 10:757-763, 1995.
39. Smith CW, Patton JG, Nadal-Ginard B. Alternative splicing in the control of gene expression. Annu Rev Genet 2:527-577, 1989.
40. Walker C, Bermudez E, Steward W, Bonner J, Molloy CJ, Everitt J. Characterization of platelet-derived growth factor and platelet-derived growth factor receptor expression in asbestos-induced rat mesothelioma. Cancer Res 52:301-306, 1992.
41. Amin KM, Litzky LA, Smythe WR, et al. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 146:344-356, 1995.
42. Langerak AW, Williamson KA, Miyagawa K, et al. Expression of the Wilms' tumor gene WT1 in human malignant mesothelioma cell lines and relationship to platelet-derived growth factor A and insulin-like growth factor 2 expression. Genes Chromosomes Cancer 12:87-96, 1995.
43. Wignal BK, Fox AJ. Mortality of female gasmask assemblers. British Journal of Industrial Medicine 39:34-48, 1982.
44. Hobbs MST, Woodward SD, Murphy B, Musk AW, Elder JE. The incidence of pneumoconiosis, mesothelioma and other respiratory cancer in men engaged in mining and milling crocidolite in western Australia. IARC Sci Publ 30:615-625, 1980.
45. Warheit DB, Driscoll KE, Oberdoerster G, et al. Contemporary issues in fiber toxicology. Fundam Appl Toxicol 25:171-183, 1995.
46. Davis JM, Bolton RE, Miller BG, Niven K. Mesothelioma dose response following intraperitoneal injection of mineral fibers. Int J Exp Pathol 72:263-274, 1991.
47. Browne K, Smither WJ. Asbestos-related mesothelioma: Factors discriminating between pleural and peritoneal sites. British Journal of Industrial Medicine 40:145-152, 1983.